Conclusions
Collective evidence from observational studies indicate a good quality
evidence on the significant association between ACEIs/ARBs use and
reduction in death and death/ICU admission, but poor-quality evidence on
both reducing severe COVID-19 and increasing hospitalisation. Our
findings further support the current recommendations of not
discontinuing ACEIs/ARBs therapy in patients with COVID-19.